Last 12 months
Inside the activity.
1 purchase rows · 32 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 8 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 14 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 7 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2022 Filed Apr 5, 2022 00:11 UTC |
Haley Patrick J.EVP, Commercial
|
SaleCommon Stock | 10,000 | $22.43 | $224,300.00 |
DisclosureSEC source: 0000939767-22-000041 · wf-form4_164911744920111.xml · nonDerivative · entry 2 Haley Patrick J. · CIK 0001692954 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,191 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 1, 2022. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.32 to $22.55. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| March 31, 2022 Filed Apr 5, 2022 00:11 UTC |
Haley Patrick J.EVP, Commercial
|
Exercise / conversionCommon Stock | 10,000 | $6.21 | $62,100.00 |
DisclosureSEC source: 0000939767-22-000041 · wf-form4_164911744920111.xml · nonDerivative · entry 1 Haley Patrick J. · CIK 0001692954 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 175,508 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 00:17 UTC |
Hessekiel JeffreyEVP, General Counsel & Sec
|
SaleCommon Stock | 13,283 | $22.00 | $292,226.00 |
DisclosureSEC source: 0000939767-22-000040 · wf-form4_164868581583503.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 605,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2020. Read SEC document |
| March 28, 2022 Filed Mar 31, 2022 00:17 UTC |
Hessekiel JeffreyEVP, General Counsel & Sec
|
SaleCommon Stock | 4,717 | $22.00 | $103,774.00 |
DisclosureSEC source: 0000939767-22-000040 · wf-form4_164868581583503.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 618,519 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2020. F2 · balance_after: Includes 144,482 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 02:04 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
GrantCommon Stock | 270,415 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-22-000039 · wf-form4_164679142275391.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,271 F3 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F4 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2023 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F5 · balance_after: Includes 340,655 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 01:57 UTC |
Senner Christopher J.EVP and CFO
|
GrantCommon Stock | 75,985 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-22-000038 · wf-form4_164679104886123.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,833 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2023 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3 · balance_after: Includes 166,165 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 01:56 UTC |
Hessekiel JeffreyEVP, General Counsel & Sec
|
GrantCommon Stock | 67,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-22-000037 · wf-form4_164679097435243.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623,236 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2023 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3 · balance_after: Includes 144,482 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 01:54 UTC |
Haley Patrick J.EVP, Commercial
|
GrantCommon Stock | 70,715 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-22-000036 · wf-form4_164679082457042.xml · nonDerivative · entry 1 Haley Patrick J. · CIK 0001692954 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,191 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2023 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3 · balance_after: Includes 175,508 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 01:52 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
GrantCommon Stock | 59,490 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-22-000035 · wf-form4_164679071956142.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,485 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2023 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3 · balance_after: Includes 132,731 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 02, 2022 Filed Mar 9, 2022 02:04 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
GiftCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-22-000039 · wf-form4_164679142275391.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 1,196,316 F1 · kind: Represents shares of Exelixis, Inc. common stock that the Reporting Person donated as a gift to a donor advised fund. F2 · ownership.nature: Shares held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 01:07 UTC |
Garber Alan MDirector
|
Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $3.13 | $0.00 |
DisclosureSEC source: 0000939767-22-000034 · wf-form4_164635603258608.xml · derivative · entry 3 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2022-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 28, 2015. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 01:07 UTC |
Garber Alan MDirector
|
SaleCommon Stock | 21,301 | $21.00 | $447,321.00 |
DisclosureSEC source: 0000939767-22-000034 · wf-form4_164635603258608.xml · nonDerivative · entry 2 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,417 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2021. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.00 to $21.01. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 01:07 UTC |
Garber Alan MDirector
|
Exercise / conversionCommon Stock | 40,000 | $3.13 | $125,200.00 |
DisclosureSEC source: 0000939767-22-000034 · wf-form4_164635603258608.xml · nonDerivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 01:09 UTC |
Haley Patrick J.EVP, Commercial
|
SaleCommon Stock | 31,238 | $19.53 | $610,078.14 |
DisclosureSEC source: 0000939767-22-000032 · wf-form4_164609696172106.xml · nonDerivative · entry 1 Haley Patrick J. · CIK 0001692954 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,476 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.53 to $19.57. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. F2 · balance_after: Includes 104,793 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 24, 2022 Filed Mar 1, 2022 01:11 UTC |
Hessekiel JeffreyEVP and General Counsel
|
SaleCommon Stock | 18,000 | $20.00 | $360,000.00 |
DisclosureSEC source: 0000939767-22-000033 · wf-form4_164609706715946.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 555,361 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2020. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.01. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. F3 · balance_after: Includes 76,607 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 01:22 UTC |
PAPADOPOULOS STELIOSDirector
|
SaleCommon Stock | 84,515 | $19.56 | $1,653,113.40 |
DisclosureSEC source: 0000939767-22-000031 · wf-form4_164575210475580.xml · nonDerivative · entry 1 PAPADOPOULOS STELIOS · CIK 0001202098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,220,036 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.37 to $19.73. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. F2 · balance_after: Includes 16,424 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 01:20 UTC |
FELDBAUM CARL BDirector
|
Exercise / conversionOption (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.13 | $0.00 |
DisclosureSEC source: 0000939767-22-000030 · wf-form4_164575203840999.xml · derivative · entry 3 FELDBAUM CARL B · CIK 0001326377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2022-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 28, 2015. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 01:20 UTC |
FELDBAUM CARL BDirector
|
SaleCommon Stock | 20,000 | $19.49 | $389,800.00 |
DisclosureSEC source: 0000939767-22-000030 · wf-form4_164575203840999.xml · nonDerivative · entry 2 FELDBAUM CARL B · CIK 0001326377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,521 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.48 to $19.49. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 01:20 UTC |
FELDBAUM CARL BDirector
|
Exercise / conversionCommon Stock | 20,000 | $3.13 | $62,600.00 |
DisclosureSEC source: 0000939767-22-000030 · wf-form4_164575203840999.xml · nonDerivative · entry 1 FELDBAUM CARL B · CIK 0001326377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:09 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
Tax withholdingCommon Stock | 17,651 | $18.59 | $328,132.09 |
DisclosureSEC source: 0000939767-22-000021 · wf-form4_164514655521783.xml · nonDerivative · entry 2 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,995 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 20, 2019, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on February 3, 2021. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:09 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
Tax withholdingCommon Stock | 2,526 | $18.59 | $46,958.34 |
DisclosureSEC source: 0000939767-22-000021 · wf-form4_164514655521783.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,646 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on February 3, 2021. F2 · balance_after: Includes 73,241 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:06 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Tax withholdingCommon Stock | 59,044 | $18.59 | $1,097,627.96 |
DisclosureSEC source: 0000939767-22-000019 · wf-form4_164514636044976.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,856 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 20, 2019, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on February 3, 2021. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:06 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Tax withholdingCommon Stock | 6,103 | $18.59 | $113,454.77 |
DisclosureSEC source: 0000939767-22-000019 · wf-form4_164514636044976.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,900 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on February 3, 2021. F2 · balance_after: Includes 70,240 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:04 UTC |
Senner Christopher J.EVP and CFO
|
Tax withholdingCommon Stock | 15,626 | $18.59 | $290,487.34 |
DisclosureSEC source: 0000939767-22-000018 · wf-form4_164514623486592.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,848 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 20, 2019, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on February 3, 2021. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:04 UTC |
Senner Christopher J.EVP and CFO
|
Tax withholdingCommon Stock | 2,701 | $18.59 | $50,211.59 |
DisclosureSEC source: 0000939767-22-000018 · wf-form4_164514623486592.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,474 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on February 3, 2021. F2 · balance_after: Includes 90,180 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 00:59 UTC |
Haley Patrick J.EVP, Commercial
|
Tax withholdingCommon Stock | 14,729 | $18.59 | $273,812.11 |
DisclosureSEC source: 0000939767-22-000017 · wf-form4_164514597737299.xml · nonDerivative · entry 2 Haley Patrick J. · CIK 0001692954 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,714 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 20, 2019, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on February 3, 2021. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 00:59 UTC |
Haley Patrick J.EVP, Commercial
|
Tax withholdingCommon Stock | 798 | $18.59 | $14,834.82 |
DisclosureSEC source: 0000939767-22-000017 · wf-form4_164514597737299.xml · nonDerivative · entry 1 Haley Patrick J. · CIK 0001692954 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,443 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on February 3, 2021. F2 · balance_after: Includes 104,793 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:07 UTC |
Hessekiel JeffreyEVP and General Counsel
|
Tax withholdingCommon Stock | 11,209 | $18.59 | $208,375.31 |
DisclosureSEC source: 0000939767-22-000020 · wf-form4_164514645487379.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 573,361 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 20, 2019, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on February 3, 2021. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:07 UTC |
Hessekiel JeffreyEVP and General Counsel
|
Tax withholdingCommon Stock | 1,017 | $18.59 | $18,906.03 |
DisclosureSEC source: 0000939767-22-000020 · wf-form4_164514645487379.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584,570 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on February 3, 2021. F2 · balance_after: Includes 76,607 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 03, 2022 Filed Feb 5, 2022 02:52 UTC |
Haley Patrick J.EVP, Commercial
|
Exercise / conversionOption (right to buy) · Derivative | 60,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0000939767-22-000011 · wf-form4_164402950927512.xml · derivative · entry 5 Haley Patrick J. · CIK 0001692954 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2022-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 85,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| February 03, 2022 Filed Feb 5, 2022 02:52 UTC |
Haley Patrick J.EVP, Commercial
|
SaleCommon Stock | 60,000 | $17.91 | $1,074,600.00 |
DisclosureSEC source: 0000939767-22-000011 · wf-form4_164402950927512.xml · nonDerivative · entry 2 Haley Patrick J. · CIK 0001692954 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,241 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2021. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.76 to $18.04. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| February 03, 2022 Filed Feb 5, 2022 02:52 UTC |
Haley Patrick J.EVP, Commercial
|
Exercise / conversionCommon Stock | 60,000 | $1.90 | $114,000.00 |
DisclosureSEC source: 0000939767-22-000011 · wf-form4_164402950927512.xml · nonDerivative · entry 1 Haley Patrick J. · CIK 0001692954 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 136,748 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| January 04, 2022 Filed Jan 7, 2022 01:02 UTC |
Goodman Vicki LEVP, Prod Dev & Med Aff &CMO
|
Tax withholdingCommon Stock | 7,613 | $19.18 | $146,017.34 |
DisclosureSEC source: 0000939767-22-000004 · wf-form4_164151735117017.xml · nonDerivative · entry 2 Goodman Vicki L · CIK 0001901477 · EVP, Prod Dev & Med Aff &CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,387 F4 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded on the Transaction Date. Read SEC document |
| January 04, 2022 Filed Jan 7, 2022 01:02 UTC |
Goodman Vicki LEVP, Prod Dev & Med Aff &CMO
|
GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-22-000004 · wf-form4_164151735117017.xml · nonDerivative · entry 1 Goodman Vicki L · CIK 0001901477 · EVP, Prod Dev & Med Aff &CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as follows: 26,315 shares subject to the restricted stock unit award vested on the Transaction Date; 59,868 shares subject to the restricted stock unit award will vest on February 15, 2023; 59,869 shares subject to the restricted stock unit award will vest on February 15, 2024; and 51,974 shares subject to the restricted stock unit award will vest on each of February 15, 2025 and February 15, 2026. F3 · balance_after: Includes 223,685 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| December 23, 2021 Filed Feb 15, 2022 02:01 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
GiftCommon Stock | 11,003 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-22-000012 · wf-form5_164489043888525.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 1,246,316 F1 · kind: On December 23, 2021, the Reporting Person gifted 11,003 shares of Exelixis, Inc. common stock to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended. F3 · ownership.nature: Shares held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended. Read SEC document |
| December 23, 2021 Filed Feb 15, 2022 02:01 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
GiftCommon Stock | 11,003 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-22-000012 · wf-form5_164489043888525.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,003 F1 · kind: On December 23, 2021, the Reporting Person gifted 11,003 shares of Exelixis, Inc. common stock to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended. F2 · balance_after: Includes 194,003 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| December 16, 2021 Filed Dec 18, 2021 01:30 UTC |
Wright JacquelineDirector
|
GrantOption (right to buy) · Derivative | 41,717 | $0.00 Strike: $17.63 | $0.00 |
DisclosureSEC source: 0000939767-21-000113 · wf-form4_163979103945065.xml · derivative · entry 2 Wright Jacqueline · CIK 0001806405 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,717 Underlying: Common Stock · 41,717 shares Expires 2028-12-15 F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the Transaction Date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the Transaction Date, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| December 16, 2021 Filed Dec 18, 2021 01:30 UTC |
Wright JacquelineDirector
|
GrantCommon Stock | 20,858 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000113 · wf-form4_163979103945065.xml · nonDerivative · entry 1 Wright Jacqueline · CIK 0001806405 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,858 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on each of the first four anniversaries of the Transaction Date, subject to the Reporting Person's continuous service through such dates. F3 · balance_after: Includes 20,858 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| December 15, 2021 Filed Dec 18, 2021 01:41 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Tax withholdingCommon Stock | 12,236 | $17.00 | $208,012.00 |
DisclosureSEC source: 0000939767-21-000117 · wf-form4_163979168754039.xml · nonDerivative · entry 4 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,006 F8 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on December 15, 2021. Read SEC document |
| December 15, 2021 Filed Dec 18, 2021 01:41 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
GrantCommon Stock | 46,478 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000117 · wf-form4_163979168754039.xml · nonDerivative · entry 3 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,242 F4 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F5 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award under the Exelixis, Inc. 2017 Equity Incentive Plan covering 46,478 shares of common stock. The PSU award generally vests as follows: (i) 50% of the original number of shares subject to the award vest upon certification by the Compensation Committee (the "Committee") that Exelixis, Inc. has achieved certain performance criteria related to the submission of Investigational New Drug applications with the U.S. Food and Drug Administration, or equivalent applications or filings with a foreign governmental authority, with respect to product candidates discovered, in-licensed or acquired by Exelixis, Inc. (the "2018 PSU Goal"); and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. F6 · shares: On December 15, 2021, the Committee convened to determine that the 2018 PSU Goal had been achieved, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on February 15, 2023, subject to the Reporting Person's continuous service through that date. F7 · balance_after: Includes 194,003 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| December 15, 2021 Filed Dec 18, 2021 01:38 UTC |
Haley Patrick J.EVP, Commercial
|
Tax withholdingCommon Stock | 1,556 | $17.00 | $26,452.00 |
DisclosureSEC source: 0000939767-21-000116 · wf-form4_163979150653476.xml · nonDerivative · entry 2 Haley Patrick J. · CIK 0001692954 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,241 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on December 15, 2021. Read SEC document |
| December 15, 2021 Filed Dec 18, 2021 01:38 UTC |
Haley Patrick J.EVP, Commercial
|
GrantCommon Stock | 8,995 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000116 · wf-form4_163979150653476.xml · nonDerivative · entry 1 Haley Patrick J. · CIK 0001692954 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,797 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award under the Exelixis, Inc. 2017 Equity Incentive Plan covering 8,995 shares of common stock. The PSU award generally vests as follows: (i) 50% of the original number of shares subject to the award vest upon certification by the Compensation Committee (the "Committee") that Exelixis, Inc. has achieved certain performance criteria related to the submission of Investigational New Drug applications with the U.S. Food and Drug Administration, or equivalent applications or filings with a foreign governmental authority, with respect to product candidates discovered, in-licensed or acquired by Exelixis, Inc. (the "2018 PSU Goal"); and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. F3 · shares: On December 15, 2021, the Committee convened to determine that the 2018 PSU Goal had been achieved, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on February 15, 2023, subject to the Reporting Person's continuous service through that date. F4 · balance_after: Includes 136,748 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| December 15, 2021 Filed Dec 18, 2021 01:35 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
Exercise / conversionOption (right to buy) · Derivative | 47,500 | $0.00 Strike: $6.21 | $0.00 |
DisclosureSEC source: 0000939767-21-000115 · wf-form4_163979129617804.xml · derivative · entry 6 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,500 shares Expires 2022-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option, representing the right to purchase a total of 190,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 16, 2019. Read SEC document |
| December 15, 2021 Filed Dec 18, 2021 01:35 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
SaleCommon Stock | 47,500 | $17.44 | $828,400.00 |
DisclosureSEC source: 0000939767-21-000115 · wf-form4_163979129617804.xml · nonDerivative · entry 4 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,172 F6 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2021. F7 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.95 to $17.86. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 7 to this Form 4. Read SEC document |
| December 15, 2021 Filed Dec 18, 2021 01:35 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
Exercise / conversionCommon Stock | 47,500 | $6.21 | $294,975.00 |
DisclosureSEC source: 0000939767-21-000115 · wf-form4_163979129617804.xml · nonDerivative · entry 3 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2021 Filed Dec 18, 2021 01:35 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
Tax withholdingCommon Stock | 4,646 | $17.00 | $78,982.00 |
DisclosureSEC source: 0000939767-21-000115 · wf-form4_163979129617804.xml · nonDerivative · entry 2 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,172 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on December 15, 2021. Read SEC document |
| December 15, 2021 Filed Dec 18, 2021 01:35 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
GrantCommon Stock | 18,741 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000115 · wf-form4_163979129617804.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,818 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award under the Exelixis, Inc. 2017 Equity Incentive Plan covering 18,741 shares of common stock. The PSU award generally vests as follows: (i) 50% of the original number of shares subject to the award vest upon certification by the Compensation Committee (the "Committee") that Exelixis, Inc. has achieved certain performance criteria related to the submission of Investigational New Drug applications with the U.S. Food and Drug Administration, or equivalent applications or filings with a foreign governmental authority, with respect to product candidates discovered, in-licensed or acquired by Exelixis, Inc. (the "2018 PSU Goal"); and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. F3 · shares: On December 15, 2021, the Committee convened to determine that the 2018 PSU Goal had been achieved, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on February 15, 2023, subject to the Reporting Person's continuous service through that date. F4 · balance_after: Includes 113,573 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| December 15, 2021 Filed Dec 18, 2021 01:32 UTC |
Senner Christopher J.EVP and CFO
|
Tax withholdingCommon Stock | 5,131 | $17.00 | $87,227.00 |
DisclosureSEC source: 0000939767-21-000114 · wf-form4_163979112340680.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,175 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on December 15, 2021. Read SEC document |
| December 15, 2021 Filed Dec 18, 2021 01:32 UTC |
Senner Christopher J.EVP and CFO
|
GrantCommon Stock | 19,491 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000114 · wf-form4_163979112340680.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,306 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award under the Exelixis, Inc. 2017 Equity Incentive Plan covering 19,491 shares of common stock. The PSU award generally vests as follows: (i) 50% of the original number of shares subject to the award vest upon certification by the Compensation Committee (the "Committee") that Exelixis, Inc. has achieved certain performance criteria related to the submission of Investigational New Drug applications with the U.S. Food and Drug Administration, or equivalent applications or filings with a foreign governmental authority, with respect to product candidates discovered, in-licensed or acquired by Exelixis, Inc. (the "2018 PSU Goal"); and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. F3 · shares: On December 15, 2021, the Committee convened to determine that the 2018 PSU Goal had been achieved, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on February 15, 2023, subject to the Reporting Person's continuous service through that date. F4 · balance_after: Includes 124,759 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| December 15, 2021 Filed Dec 18, 2021 01:26 UTC |
Hessekiel JeffreyEVP and General Counsel
|
Tax withholdingCommon Stock | 2,621 | $17.00 | $44,557.00 |
DisclosureSEC source: 0000939767-21-000111 · wf-form4_163979079438564.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 585,587 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on December 15, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.